6 June 2016 - The TGA has published AusPARs for talimogene laherparepvec (Imlygic) & naloxegol oxalate (Movantik).

The TGA has published AusPARs for Amgen's Imlygic and AstraZeneca's Movantik.

The TGA approved Imylgic on 18 December 2015 for use as monotherapy for the treatment of melanoma in patients with unresectable cutaneous, subcutaneous or nodal lesions after initial surgery.

The TGA approved Movantik on 5 January 2016 for the treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxative(s).

For more details, go to: http://www.tga.gov.au/australian-public-assessment-reports-prescription-medicines-auspars